Pacira BioSciences stockholders approve stock plan adding 2,500,000 shares
At its June 10, 2025 annual meeting, Pacira BioSciences stockholders approved an amended and restated 2011 Stock Incentive Plan that increases the shares authorized for grant by 2,500,000, and elected three Class II directors. Stockholders rejected the advisory say-on-pay vote, with 22,595,202 votes against and 14,752,829 for, and the board will hold say-on-pay votes every year.
Key points
- Stock incentive plan approved: 22,043,902 for, 15,317,588 against, 20,318 abstain, 8,909,022 broker non-votes; 2,500,000 newly reserved shares
- Advisory say-on-pay vote failed: 14,752,829 for, 22,595,202 against, 33,777 abstain; board will hold these votes annually
- Marcelo Bigal, Frank D. Lee and Alethia Young elected as Class II directors to serve until the 2028 annual meeting; KPMG LLP ratified for fiscal 2025 with 40,022,569 for
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 13, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.